A Randomized, Open-label, Blind-analysis, Parallel Group, Multicenter Study to Evaluate the Efficacy on Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin

Trial Profile

A Randomized, Open-label, Blind-analysis, Parallel Group, Multicenter Study to Evaluate the Efficacy on Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2017

At a glance

  • Drugs Alirocumab (Primary) ; Anticoagulants; Antiplatelets; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate; Rosuvastatin
  • Indications Acute coronary syndromes; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ODYSSEY J-IVUS
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top